Global burden of disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries.
Cancer
Chewing
Ischaemic heart disease
Mouth
Oesophagus
Oral
Pharynx
Smokeless tobacco
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
12 08 2020
12 08 2020
Historique:
received:
21
04
2020
accepted:
23
06
2020
entrez:
13
8
2020
pubmed:
13
8
2020
medline:
11
2
2021
Statut:
epublish
Résumé
Smokeless tobacco (ST) is consumed by more than 300 million people worldwide. The distribution, determinants and health risks of ST differ from that of smoking; hence, there is a need to highlight its distinct health impact. We present the latest estimates of the global burden of disease due to ST use. The ST-related disease burden was estimated for all countries reporting its use among adults. Using systematic searches, we first identified country-specific prevalence of ST use in men and women. We then revised our previously published disease risk estimates for oral, pharyngeal and oesophageal cancers and cardiovascular diseases by updating our systematic reviews and meta-analyses of observational studies. The updated country-specific prevalence of ST and disease risk estimates, including data up to 2019, allowed us to revise the population attributable fraction (PAF) for ST for each country. Finally, we estimated the disease burden attributable to ST for each country as a proportion of the DALYs lost and deaths reported in the 2017 Global Burden of Disease study. ST use in adults was reported in 127 countries; the highest rates of consumption were in South and Southeast Asia. The risk estimates for cancers were also highest in this region. In 2017, at least 2.5 million DALYs and 90,791 lives were lost across the globe due to oral, pharyngeal and oesophageal cancers that can be attributed to ST. Based on risk estimates obtained from the INTERHEART study, over 6 million DALYs and 258,006 lives were lost from ischaemic heart disease that can be attributed to ST. Three-quarters of the ST-related disease burden was among men. Geographically, > 85% of the ST-related burden was in South and Southeast Asia, India accounting for 70%, Pakistan for 7% and Bangladesh for 5% DALYs lost. ST is used across the globe and poses a major public health threat predominantly in South and Southeast Asia. While our disease risk estimates are based on a limited evidence of modest quality, the likely ST-related disease burden is substantial. In high-burden countries, ST use needs to be regulated through comprehensive implementation of the World Health Organization Framework Convention for Tobacco Control.
Sections du résumé
BACKGROUND
Smokeless tobacco (ST) is consumed by more than 300 million people worldwide. The distribution, determinants and health risks of ST differ from that of smoking; hence, there is a need to highlight its distinct health impact. We present the latest estimates of the global burden of disease due to ST use.
METHODS
The ST-related disease burden was estimated for all countries reporting its use among adults. Using systematic searches, we first identified country-specific prevalence of ST use in men and women. We then revised our previously published disease risk estimates for oral, pharyngeal and oesophageal cancers and cardiovascular diseases by updating our systematic reviews and meta-analyses of observational studies. The updated country-specific prevalence of ST and disease risk estimates, including data up to 2019, allowed us to revise the population attributable fraction (PAF) for ST for each country. Finally, we estimated the disease burden attributable to ST for each country as a proportion of the DALYs lost and deaths reported in the 2017 Global Burden of Disease study.
RESULTS
ST use in adults was reported in 127 countries; the highest rates of consumption were in South and Southeast Asia. The risk estimates for cancers were also highest in this region. In 2017, at least 2.5 million DALYs and 90,791 lives were lost across the globe due to oral, pharyngeal and oesophageal cancers that can be attributed to ST. Based on risk estimates obtained from the INTERHEART study, over 6 million DALYs and 258,006 lives were lost from ischaemic heart disease that can be attributed to ST. Three-quarters of the ST-related disease burden was among men. Geographically, > 85% of the ST-related burden was in South and Southeast Asia, India accounting for 70%, Pakistan for 7% and Bangladesh for 5% DALYs lost.
CONCLUSIONS
ST is used across the globe and poses a major public health threat predominantly in South and Southeast Asia. While our disease risk estimates are based on a limited evidence of modest quality, the likely ST-related disease burden is substantial. In high-burden countries, ST use needs to be regulated through comprehensive implementation of the World Health Organization Framework Convention for Tobacco Control.
Identifiants
pubmed: 32782007
doi: 10.1186/s12916-020-01677-9
pii: 10.1186/s12916-020-01677-9
pmc: PMC7422596
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
222Subventions
Organisme : National Institute for Health Research
ID : 17/63/76
Pays : International
Références
Tob Control. 2011 May;20(3):e2
pubmed: 21109685
Epidemiology. 2005 Jan;16(1):12-6
pubmed: 15613940
Eur J Cancer. 2012 Mar;48(5):655-61
pubmed: 21733677
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Br J Cancer. 1965 Dec;19(4):642-60
pubmed: 5867785
Int J Cancer. 2008 Jul 1;123(1):168-73
pubmed: 18412245
Int J Cancer. 2002 Mar 20;98(3):440-5
pubmed: 11920597
Int J Cancer. 1998 Jul 29;77(3):341-6
pubmed: 9663593
Harm Reduct J. 2013 Dec 06;10:36
pubmed: 24314326
Drug Alcohol Depend. 2014 Jun 1;139:60-70
pubmed: 24685560
Nicotine Tob Res. 2019 Aug 29;:
pubmed: 31570940
BMC Cardiovasc Disord. 2009 May 27;9:21
pubmed: 19473535
Int J Cancer. 2013 Apr 15;132(8):1911-7
pubmed: 22987222
Int J Cancer. 2000 Apr 1;86(1):128-31
pubmed: 10728606
BMC Med. 2015 Aug 17;13:194
pubmed: 26278072
Indian J Cancer. 2012 Apr-Jun;49(2):245-50
pubmed: 23107978
J Epidemiol Community Health. 1990 Dec;44(4):286-92
pubmed: 2277249
PLoS One. 2013 Apr 15;8(4):e60996
pubmed: 23596512
Br J Cancer. 1990 Nov;62(5):847-51
pubmed: 2245179
Toxicol Lett. 2016 Jul 8;254:45-51
pubmed: 27178269
Cancer Causes Control. 2002 Sep;13(7):609-16
pubmed: 12296508
Addict Health. 2018 Jan;10(1):52-63
pubmed: 30627385
Tob Control. 2018 Jan;27(1):35-42
pubmed: 27903956
Lancet. 2007 Jun 16;369(9578):2015-2020
pubmed: 17498797
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Sultan Qaboos Univ Med J. 2015 Nov;15(4):e469-76
pubmed: 26629372
Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):55-8
pubmed: 14744733
Epidemiology. 2008 Nov;19(6):794-9
pubmed: 18854704
Int J Cancer. 2000 Feb 1;85(3):340-6
pubmed: 10652424
Nicotine Tob Res. 2013 Jul;15(7):1283-8
pubmed: 23288872
Cancer Sci. 2011 Feb;102(2):460-7
pubmed: 21129124
Br J Cancer. 2009 Mar 10;100(5):848-52
pubmed: 19259098
Eur J Cancer Prev. 2007 Jun;16(3):251-6
pubmed: 17415096
J Intern Med. 2007 Sep;262(3):360-7
pubmed: 17697157
Cancer. 1971 Jul;28(1):244-52
pubmed: 5110639
Eur J Epidemiol. 1990 Jun;6(2):219-22
pubmed: 2361546
Cancer Control. 2020 Jan-Dec;27(1):1073274820914659
pubmed: 32208972
J Intern Med. 2007 Sep;262(3):351-9
pubmed: 17697156
PLoS One. 2012;7(1):e30584
pubmed: 22276217
Acta Otolaryngol. 2005 Sep;125(9):991-8
pubmed: 16193590
Oral Oncol. 2008 May;44(5):446-54
pubmed: 17933578
Eur J Prev Cardiol. 2016 Dec;23(18):1970-1981
pubmed: 27256827
BMJ. 1992 Nov 21;305(6864):1252-6
pubmed: 1477567
Int J Cancer. 2003 Jul 10;105(5):681-6
pubmed: 12740918
Food Chem Toxicol. 2013 Jul;57:380-6
pubmed: 23517910
Rural Remote Health. 2017 Jul-Sep;17(3):4044
pubmed: 28780876
Nicotine Tob Res. 2020 Feb 08;:
pubmed: 32034915
Lancet Oncol. 2019 Apr;20(4):e208-e217
pubmed: 30942182
BMC Med. 2014 Dec 18;12:243
pubmed: 25518855
Food Chem Toxicol. 2015 Aug;82:50-8
pubmed: 25934468
Cancer. 1993 Aug 15;72(4):1369-75
pubmed: 8339227
J Natl Cancer Inst. 1988 Dec 21;80(20):1620-5
pubmed: 3193480
Lancet. 2006 Aug 19;368(9536):647-58
pubmed: 16920470
Stroke. 2003 Jul;34(7):1754-9
pubmed: 12775887
Lancet. 2002 Nov 2;360(9343):1347-60
pubmed: 12423980
PLoS One. 2017 Jul 10;12(7):e0180445
pubmed: 28692704
Carcinogenesis. 2007 Jul;28(7):1455-62
pubmed: 17307803
Int J Cancer. 2007 Oct 15;121(8):1793-8
pubmed: 17583577
Cancer. 2007 Jun 15;109(12):2547-56
pubmed: 17492688
Cancer Causes Control. 2015 Mar;26(3):487-91
pubmed: 25542140
Scand J Public Health. 2007;35(6):618-22
pubmed: 17852996
Int J Cancer. 1994 Aug 15;58(4):469-73
pubmed: 8056441
Nicotine Tob Res. 2015 Sep;17(9):1058-66
pubmed: 25534929
J Intern Med. 2009 Jun;265(6):717-24
pubmed: 19504754
Br J Cancer. 2012 Oct 23;107(9):1618-23
pubmed: 23033008
Int J Cancer. 2005 May 10;114(6):992-5
pubmed: 15645430
Am J Public Health. 1994 Mar;84(3):399-404
pubmed: 8129055
Br Med J. 1955 May 7;1(4922):1111-4
pubmed: 14363805
J Am Coll Cardiol. 1999 Nov 15;34(6):1784-90
pubmed: 10577570
Sultan Qaboos Univ Med J. 2016 Feb;16(1):e20-6
pubmed: 26909208
Cancer. 1998 Apr 1;82(7):1367-75
pubmed: 9529030
Int J Cancer. 2008 Mar 1;122(5):1095-9
pubmed: 17973262
Public Health. 2008 Dec;122(12):1331-8
pubmed: 18657835
Br J Cancer. 1977 Feb;35(2):232-5
pubmed: 836760
Epidemiology. 2006 Jan;17(1):47-51
pubmed: 16357594
J Cancer Res Ther. 2015 Jan-Mar;11(1):199-203
pubmed: 25879362
Int J Epidemiol. 2000 Aug;29(4):609-14
pubmed: 10922335
Int J Drug Policy. 2015 Jun;26(6):569-74
pubmed: 25214359
Indian J Cancer. 2014 Dec;51 Suppl 1:S24-32
pubmed: 25526244
Southeast Asian J Trop Med Public Health. 1998 Dec;29(4):827-34
pubmed: 10772572